Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Sees Significant Decrease in Short Interest

Tevogen Bio Holdings Inc. (NASDAQ:TVGN) saw a large drop in short interest in the month of November. As of November 15th, there was short interest totalling 774,700 shares, a drop of 79.0% from the October 31st total of 3,690,000 shares. Currently, 3.5% of the company’s shares are short sold. Based on an average daily volume of 15,910,000 shares, the days-to-cover ratio is presently 0.0 days.

Insider Transactions at Tevogen Bio

In other news, insider Neal Flomenberg sold 1,078,600 shares of the firm’s stock in a transaction dated Thursday, October 17th. The stock was sold at an average price of $1.62, for a total value of $1,747,332.00. Following the transaction, the insider now directly owns 4,254,302 shares in the company, valued at $6,891,969.24. This trade represents a 20.23 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 56.60% of the company’s stock.

Hedge Funds Weigh In On Tevogen Bio

A hedge fund recently bought a new stake in Tevogen Bio stock. HGC Investment Management Inc. bought a new stake in shares of Tevogen Bio Holdings Inc. (NASDAQ:TVGN) during the 3rd quarter, according to its most recent filing with the SEC. The firm bought 223,077 shares of the company’s stock, valued at approximately $82,000. HGC Investment Management Inc. owned 0.13% of Tevogen Bio as of its most recent filing with the SEC.

Tevogen Bio Stock Performance

Tevogen Bio stock opened at $1.37 on Thursday. The stock’s 50-day moving average is $1.27 and its 200-day moving average is $0.89. Tevogen Bio has a 12 month low of $0.26 and a 12 month high of $21.09.

About Tevogen Bio

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.